Page 6 - Nasdaq Imrx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immuneering (NASDAQ:IMRX – Get Rating) and Inozyme Pharma (NASDAQ:INZY – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Institutional and Insider Ownership 46.8% of Immuneering shares are owned […]

Zacks Investment Research cut shares of Immuneering (NASDAQ:IMRX – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Monday morning, Zacks.com reports. According to Zacks, “Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company’s product candidate includes IMM-1-104. […]

Millennium Management LLC acquired a new position in Immuneering Corp (NASDAQ:IMRX – Get Rating) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 89,788 shares of the company’s stock, valued at approximately $2,384,000. Several other hedge funds also recently modified their holdings of […]

Millennium Management LLC acquired a new stake in shares of Immuneering Corp (NASDAQ:IMRX – Get Rating) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 89,788 shares of the company’s stock, valued at approximately $2,384,000. Other hedge funds and other institutional investors have also […]

Brokerages forecast that Immuneering Corp (NASDAQ:IMRX – Get Rating) will announce $230,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Immuneering’s earnings, with estimates ranging from $190,000.00 to $300,000.00. The business is scheduled to announce its next quarterly earnings results on Thursday, June 9th. On average, […]